HR of mortality among HIV-infected people receiving ART
| Characteristics | Univariable | Multivariable | ||
| HR (95%CI) | P value | HR (95%CI) | P value | |
| Gender | ||||
| Male | Reference | Reference | ||
| Female | 0.65 (0.51 to 0.82) | <0.001 | 0.80 (0.63 to 1.03) | 0.079 |
| Ethnicity | ||||
| Non-indigenous | Reference | Reference | ||
| Indigenous | 1.10 (0.89 to 1.36) | 0.381 | 1.07 (0.86 to 1.34) | 0.538 |
| Age | ||||
| ≤36 years | Reference | Reference | ||
| >36 years | 0.93 (0.75 to 1.15) | 0.511 | 0.74 (0.59 to 0.92) | 0.008 |
| Residence | ||||
| Valley | Reference | Reference | ||
| Hill | 0.87 (0.67 to 1.11) | 0.259 | 0.77 (0.60 to 1.01) | 0.057 |
| Terai | 1.11 (0.85 to 1.46) | 0.428 | 0.92 (0.70 to 1.22) | 0.565 |
| Clinical stage | ||||
| Stage I | Reference | Reference | ||
| Stage II | 0.81 (0.53 to 1.26) | 0.353 | 0.84 (0.54 to 1.31) | 0.442 |
| Stage III | 2.15 (1.51 to 3.05) | <0.001 | 1.82 (1.26 to 2.62) | 0.001 |
| Stage IV | 5.86 (4.15 to 8.28) | <0.001 | 3.73 (2.58 to 5.41) | <0.001 |
| CD4 cell count (cells/cm3) | ||||
| ≤50 | Reference | Reference | ||
| 51–100 | 0.94 (0.70 to 1.26) | 0.675 | 1.06 (0.79 to 1.42) | 0.685 |
| 101–200 | 0.49 (0.37 to 0.65) | <0.001 | 0.71 (0.53 to 0.95) | 0.023 |
| >200 | 0.19 (0.13 to 0.29) | <0.001 | 0.32 (0.21 to 0.49) | <0.001 |
ART, antiretroviral therapy.